CMO incidence post cataract surgery with/out prostaglandin analogues
Research type
Research Study
Full title
The effect of prostaglandin analogue treatment on the incidence of cystoid macular oedema following uncomplicated cataract surgery.
IRAS ID
147580
Contact name
Nuwan Niyadurupola
Contact email
Sponsor organisation
Norfolk & Norwich University Hospital
Research summary
Prostaglandin analogue (PGA ) eye drops are used to reduce eye pressure and prevent deterioration of vision in eyes with glaucoma. However, there are reports that after cataract surgery some patients on PGA eye drops develop cystoid macular oedema (CMO) (a reversible swelling of the retina of the eye that causes blurred vision). It is unknown whether a patient should continue with the PGA eye drop to keep their eye pressure under control after cataract surgery or should stop their PGA eye drop to prevent the occurrence of CMO.
A paper (Miyake K, Arch Ophthalmol 1999, 117:34–40) showed that the incidence of CMO was significantly higher when PGAs are used post operatively. But this paper used postsurgical anti-inflammatory eye drops (fluorometholone) that are much weaker than what is routinely used in the UK (dexamethasone) after cataract surgery. Since stronger steroids (dexamethasone) have been shown to reduce the risk of CMO, the effect of the use of PGA eye drops with the concurrent use of Dexamethasone eye drops is unknown.
This study will determine the rate of CMO in eyes with glaucoma that have PGA eye drops stopped and those that don't whilst being given routine post operative drops (dexamethasone).
Patients will be randomised into 2 groups of post operative treatment :
1. Continue with PGA eye drops
2. Stop PGA eye drops
(All patients will receive dexamethasone eye drops as is standard practice).REC name
East of England - Cambridge South Research Ethics Committee
REC reference
14/EE/1064
Date of REC Opinion
1 Aug 2014
REC opinion
Unfavourable Opinion